Sunshine Biopharma Inc. (NASDAQ: SBFM) announced on Wednesday that it has secured regulatory approval to introduce its generic Enalapril tablets across the Canadian market. The newly approved medication, the generic equivalent of the brand Vasotec, will be available in multiple dosage strengths: 2.5mg, 5mg, 10mg, and 20mg tablets. This approval signals a significant strategic step into first-line antihypertensive treatments.

Enalapril belongs to the class of medications known as ACE (Angiotensin-Converting Enzyme) inhibitors. These drugs work by relaxing blood vessels to improve blood flow and heart efficiency. The medication is widely prescribed to lower high blood pressure, reduce the risk of stroke and heart attack, and improve survival rates in patients with heart failure.

Market Context

The approval aligns with broader growth trends in the cardiovascular sector. According to BioSpace, the global anti-hypertensive drug market was valued at $25.94 billion in 2025 and is projected to reach $37.24 billion by 2034, expanding at a compound annual growth rate (CAGR) of 4.1%.

Canada represents a significant opportunity within this landscape, accounting for approximately 2.1% of the global pharmaceutical market and ranking as the sixth largest worldwide, according to IQVIA Pharmafocus 2028.

Distribution Strategy

Sunshine Biopharma will leverage its wholly owned Canadian subsidiary, Nora Pharma Inc., to distribute the new product. The company has established a robust distribution network across Canada, positioning it to capitalize on the demand for first-line hypertension therapies as soon as production is ready. Retail pharmacies across Canada can expect to receive their initial shipments of the newly approved generic medication by the close of 2026.

"With the introduction of Enalapril oral tablets, we're continuing to build a portfolio that delivers real impact," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "Enalapril is essential in managing hypertension and heart failure, and this launch enhances access to dependable, cost‑effective cardiovascular treatment for patients who need it most."

Company Portfolio Update

Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In May, the company received Canadian regulatory approval for generic amoxicillin as part of the expansion of its generic antibiotic portfolio. That product is expected to be ready to ship to pharmacies in August 2026.

In addition, the company is conducting a proprietary drug development program which includes K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections.

In June, the company concluded a one-for-ten reverse stock split to regain compliance with Nasdaq’s minimum bid price requirement for continued listing. Shares were up 1.79% at $1.13 during premarket trading on Wednesday.

Sunshine Biopharma Inc. (NASDAQ: SBFM) has launched its generic Amoxicillin formulation in the Canadian market, beginning shipments to pharmacies this week. The launch expands the company’s portfolio of essential prescription medications, adding to its existing lineup of 60 generic drugs currently on the market in Canada. This strategic move positions the company to capture share in a global Amoxicillin market estimated at $4.9 billion in 2025, driven by increasing prevalence of bacterial infections and growing adoption in pediatric and adult care.

The generic antibiotic is available in multiple dosages and strengths, ensuring broad accessibility for prescribers and pharmacists across Canada. According to data from IQVIA, OECD, and Health Canada, the Canadian market comprises approximately 2% of the global total for this drug class. The company aims to provide affordable, high-quality antibiotics while maintaining strict compliance standards.

Market Outlook

The global demand for Amoxicillin is projected to grow at a compounded annual growth rate (CAGR) of 2.9%, reaching approximately $6.4 billion by 2031. Key drivers include rising bacterial infection rates worldwide and expanded usage in both pediatric and adult healthcare settings.

Portfolio Expansion

Sunshine Biopharma currently markets 60 generic prescription drugs in Canada and has approximately 12 additional drugs scheduled for launch in the remainder of 2026. Beyond generics, the company is conducting a proprietary drug development program focused on two key candidates:

• K1.1 mRNA: An mRNA-Lipid Nanoparticle targeted for liver cancer treatment.
• PLpro protease inhibitor: A small molecule designed for the treatment of SARS Coronavirus infections.

"We are proud to add Amoxicillin to our expanding portfolio of generic antibiotics," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "This launch aligns with our mission to deliver essential medications at competitive prices while maintaining the highest standards of quality and compliance."

What the Numbers Show

The entry into the Amoxicillin market highlights Sunshine Biopharma’s focus on high-volume, essential generic therapies. With the Canadian segment representing only ~2% of the global $4.9 billion market, the immediate addressable opportunity is modest but stable. However, the broader pipeline of 12 upcoming launches in 2026 suggests a strategy of rapid portfolio diversification rather than reliance on single-product revenue spikes. The inclusion of proprietary oncology and antiviral candidates indicates a long-term shift toward higher-margin specialty drugs, though these remain in development stages.